TICKERNERD
Menu
SNWVSNWVHealthcare · Medical Devices

SNWV Stock Forecast: SANUWAVE Health, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$5.85
+5.51% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 8 Oct 2026 — in the upper half.

Market cap
$47.7M
Ticker Nerd rank
51 / 100
Median analyst target
—
Analysts covering
1
Revenue$9.7M−4.2% y/y
Operating income−$280K
Net income−$682K
Free cash flow−$22K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+26.5%
1M
+40.5%
YTD
−80.4%
1Y
−81.3%
From 52W high
−83.5%
From 52W low
+46.1%
$4
$35
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SNWV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores SANUWAVE Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
51 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
100
Size
81
Issuance
79
Value
72
Growth
59
Volatility
47
Revisions
25
Accruals
16
Momentum
1

Quality (100): The business earns solid, repeatable profits on what it owns.

Momentum (1): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SNWV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SNWV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Jan 26Apr 26Jul 26Oct 26SNWV

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
30 Mar 2026Roth CapitalReiteratesBuy$53 → $47
3 Sept 2025Northland Capital MarketsInitiatesOutperform—
22 Aug 2025Roth CapitalMaintainsBuy—
29 July 2025Roth CapitalInitiatesBuy—
15 Sept 2020Lake StreetInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SNWV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SNWV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, SANUWAVE Health, Inc. returned −81.3% against +16.2% for the S&P 500, dividends included.

SNWV vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26SNWVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SNWV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

SANUWAVE Health, Inc. (SNWV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
23.1×

Cheaper than 32% of US stocks

Price / sales
1.1×

Cheaper than 67% of US stocks

Price / book
17.1×

Cheaper than 6% of US stocks

EV / EBITDA
13.2×

Cheaper than 27% of US stocks

Growth & margins
Revenue growth (YoY)
−3.1%

Higher than 22% of US stocks

Earnings growth (YoY)
−4.2%

Higher than 31% of US stocks

Gross margin
76.2%

Higher than 88% of US stocks

Operating margin
−2.9%

Higher than 29% of US stocks

Net margin
34.7%

Higher than 92% of US stocks

Returns & dividend
Return on equity
729.6%

Higher than 99% of US stocks

Return on assets
5.5%

Higher than 79% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

SANUWAVE Health, Inc. (SNWV) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • SANUWAVE Health, Inc. has a market value of $47.7M and an enterprise value of $56.1M.

  • Revenue in the twelve months to 30 June 2026: $43.9M. The latest quarter shrank 3.1% year on year.

  • Net income over the same four quarters: $14.3M, a 32.6% net margin.

  • Free cash flow in the twelve months to 30 June 2026: $4.0M.

  • Shares outstanding: 8.6M.

  • Trailing P/E: 23.1×; forward P/E: −554.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • SANUWAVE Health, Inc. employs 55 people — $798K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

SNWV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
SNWVSANUWAVE Health, Inc.$47.7M
51
MDAISpectral AI, Inc.$50.3M
19
COCHEnvoy Medical, Inc.$50.6M
34
SRTSSensus Healthcare, Inc.$48.9M
50
TELATELA Bio, Inc.$46.8M
34
XTNTXtant Medical Holdings, Inc.$45.0M
74
MYOMyomo, Inc.$55.8M
60

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own SANUWAVE Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SNWV news & analysis

SRK Capital 2026 Semi-Annual Portfolio Update

Seeking Alpha · 21 Sept 2026neutral

SRK Capital's 2026 semi-annual portfolio update reports SRK Fund I, LP gained 26.80% in the first half of the year, outperforming the S&P 500 and Russell 2000. The update highlights strong results for portfolio companies ImmuCell and Outdoor Holding Company but makes no mention of SANUWAVE Health.

Why it matters — A SNWV watcher would care because the update contains no information about SANUWAVE, offering no direct insight into the company's performance or outlook.

SANUWAVE Health, Inc. (SNWV) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Seeking Alpha published the transcript of SANUWAVE Health, Inc.'s Q2 2026 earnings call, following the company's presentation of its quarterly results and commentary to investors.

Why it matters — The Q2 2026 earnings call transcript offers SNWV watchers direct access to management's discussion of the company's recent performance and outlook.

Sanuwave Health Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026negative

Sanuwave Health reported Q2 2026 revenue of $9.7 million, down 3% from $10.1 million a year earlier. The decline was driven by lower UltraMIST system sales, which offset continued growth in the company's recurring applicator business.

Why it matters — A revenue decline despite growth in the recurring applicator segment highlights ongoing challenges in the company's product mix and top-line performance.

Sanuwave Announces Q2 FY2026 Financial Results

GlobeNewsWire · 6 Aug 2026negative

Sanuwave announced its Q2 FY2026 financial results, reporting revenues of $9.7 million, down 3% from $10.1 million in Q2 2025. Gross margin for the quarter was 76.2%, compared to 78.1% in the prior-year quarter.

Why it matters — These results provide the latest revenue and profitability figures for Sanuwave, showing a slight year-over-year decline in both revenue and gross margin that SNWV watchers would track.

FAQ

Frequently asked questions about SNWV stock

Is SNWV stock a buy right now?

Of the 1 analysts covering SANUWAVE Health, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks SANUWAVE Health, Inc. 51 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SNWV?

As at 8 Oct 2026, SANUWAVE Health, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (100 of 100).

What is the SNWV stock forecast for 2030?

No analyst covering SANUWAVE Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SNWV are extrapolating price history, which says nothing about the business.

How has SNWV stock performed over the past year?

SANUWAVE Health, Inc. returned -81.3% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does SANUWAVE Health, Inc. do?

SANUWAVE Health, Inc. Common Stock represents a medical device company focused on noninvasive energy-based therapies for wound care and regenerative healing.

What is the latest news on SNWV?

The most recent item we track (Seeking Alpha, 21 Sept 2026): "SRK Capital 2026 Semi-Annual Portfolio Update". SRK Capital's 2026 semi-annual portfolio update reports SRK Fund I, LP gained 26.80% in the first half of the year, outperforming the S&P 500 and Russell 2000. The update highlights strong results for portfolio companies ImmuCell and Outdoor Holding Company but makes no mention of SANUWAVE Health.

Company

About SANUWAVE Health, Inc.

SANUWAVE Health, Inc. Common Stock represents a medical device company focused on noninvasive energy-based therapies for wound care and regenerative healing. SANUWAVE develops and markets ultrasound and shockwave systems designed to support the treatment of acute and chronic wounds, with its UltraMIST platform serving as a key commercial product. The company also works in related areas such as tissue, musculoskeletal, and vascular repair, positioning its technologies within advanced wound management and regenerative medicine. Its business is centered on designing and selling medical devices to healthcare providers, with products used in clinical settings that require targeted, non-contact therapeutic solutions. SANUWAVE Health, Inc. Common Stock is associated with a healthcare technology business that addresses specialized treatment needs across wound care and tissue recovery markets.

CEO Mr. Morgan C. Frank · 55 employees · United States · https://sanuwave.com